This specific anaerobic culture identifies C. difficile, which is often present in healthy individuals, but can be associated with antibiotic-associated diarrhea. If C. difficile is cultured at any level, the sample is automatically tested for all known toxigenic strains using an FDA-cleared, molecular diagnostic DNA assay at no additional charge.
Learn more »
5 to 7 days
Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.
|Toxigenic C. Difficile Culture; stool||87075||No|
List price applies when filing with insurance or Medicare, or when billing a patient directly.
Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.
Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.
The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.
Clostridia are anaerobic Gram-positive bacteria that do not grow in the more aerobic environment of the distal colon. However Clostridia produce extremely durable endospores as a means of proliferation—the spores are resistant to air, antibiotics, heat, drying and disinfectants. For this test, Doctor's Data uses growth media optimally suited for growth of Clostridium difficile and anaerobic culture conditions to germinate the spores to metabolically active bacteria that are sub-cultured for positive identification (speciation). If C. difficile is cultured at any level, the sample is automatically tested for all known toxigenic strains using an FDA-cleared, molecular diagnostic DNA assay at no additional charge. Clostridia generally are resistant to antibiotics and treatment of an overgrowth of C. difficile, especially in asymptomatic carriers and infants under age two, is usually not warranted. Additionally, since plasmids have a potential role in transferring various capacities, including antibiotic resistance, from one organism to another, the use of antibiotics in the treatment of clostridia overgrowth should be considered carefully.